Good Health Can’t Wait.

More documents

Recommendations

Info

Good Health Can’t Wait. Dr. Reddy’s Laboratories Limited 43,238 beneficiaries Reached through the Community Health Intervention Program (CHIP). We engage with the community through our partners like Dr. Reddy’s Foundation (DRF), Naandi Foundation, NICE Foundation and other similar organizations. in farming. This program helps them enhance their income by increasing productivity. In FY2015, we supported 20 farm projects. Skilling Rural Youth (SRY) is a 10-day capacity building program. It primarily focuses on soft skills, and linking rural youth with local wage employment opportunities. In FY2015, 165 young people were supported by the program. Developing change makers We trained 44 budding social change agents and NGO staff on entrepreneurial and leadership skills through CSIM. Besides, 20 social agents were trained through Acumen. These efforts resulted in social delivery projects relevant to community needs. Health Initiatives We initiated the Community Health Intervention Program (CHIP) in 55 villages and 30 gram panchayats of Ranastalam Mandal, Srikakulam district. This five-year project has been started in partnership with the NICE foundation to bring better healthcare facilities to villages. In FY2015, we reached out to 43,238 beneficiaries. The program has begun to: Enhance basic support for ante and postnatal care, safe delivery and infant care; Promote primary immunization of children by the age of one, against 10 vaccine-preventable diseases; and Increase awareness in communities, with an emphasis on health and nutrition for safe motherhood, and raise the child survival rate. Additionally, we established RO water plants and arranged health camps in our manufacturing units. 2. Are the programs/projects undertaken through in-house team/ own foundation/external NGO/ government structures/any other organization? We engage with the community through our partners like Dr. Reddy’s Foundation (DRF), Naandi Foundation, NICE Foundation and other similar organizations. 3. Have you done any impact assessment of your initiative? We review our internal assessment systems and projects from time to time. Each project has specific deliverables against which it is measured. 4. What is your company’s direct contribution to community development projects- Amount in INR and the details of the projects undertaken? We contributed ` 29.16 crores for community development. For details of the projects undertaken refer the projects listed in the CSR Report. 5. Have you taken steps to ensure that this community development initiative is successfully adopted by the community? Please explain in 50 words, or so. Our community development initiatives are designed towards sustainability. For education programs, we encourage the participation of parents in the School Management Committee (SMC) through a small contribution to instill ownership. Similarly, young people participating in the vocational skills enhancing programs pay a small percentage of the course fees. Besides, we also involve gram panchayat or local government in the project development discussions. PRINCIPLE 9 CUSTOMER VALUE 1. What percentage of customer complaints/consumer cases are pending as on the end of financial year. 13.6% of total domestic/national/ customer complaints 1 are pending, as on the end of the financial year. 2. Does the company display product information on the product label, over and above what is mandated as per local laws? Yes/No/NA/ Remarks(additional information) For different markets and products, we display product information as described below: For North America Generics’ (NAG) Oral Solid Division and Europe Generics (EUG), we provide no additional information other than what is mandatory. There are few exceptions, like Zoledronic injection for the EU market is provided with an arrow mark to peel. For NAG injectable, we provide no additional information other than what is mandatory. Some special cases are there. For example, Sumatriptan injection has an auto injector QR code and promotional information 1 The number of complaints are from India. 38
Statutory Reports • Business Responsibility Report Annual Report 2014 - 15 Our primary research team regularly conducts consumer surveys in all therapy areas. The survey carried out with Hepatitis C patients to understand their unmet needs is an example. Finished goods on the packaging line (separate component) is provided in Zoledronic Acid – Canada. For the domestic market, we sometimes provide additional information in labeling. We provide tag lines, such as ‘Tough on Pain’ on our Nise® gel packs in addition to pictorials. For all EM markets, we give only label claim, and in few cases warning, as per market requirement. 3. Is there any case filed by any stakeholder against the company regarding unfair trade practices, irresponsible advertising and/or anticompetitive behavior during the last five years and pending as on end of financial year. If so, provide details thereof, in about 50 words or so. We do not have pending litigations before any judicial or quasi-judicial forums, relating to our involvement in unfair trade practices, irresponsible advertising and/or anti-competitive behavior. However, there were a few legal notices issued by certain individuals in relation to the above claims. Such notices have not ended in any litigation as on date. 4. Did your company carry out any consumer survey/consumer satisfaction trends? Our primary research team regularly conducts consumer surveys in all therapy areas. One such example is the survey carried out with Hepatitis C patients to understand their unmet needs with sensitivity. It helped us design services for patients to aid them with our therapy. We have carried out more such surveys for products like Venusia®, Razo and in the space of nephrology. Such surveys helped us get useful feedback on our products. 39
Page 1 and 2: ANNUAL REPORT 2014-15 Good Health C
Page 3 and 4: Our Brand We are in the business of
Page 5 and 6: Corporate Overview Annual Report 20
Page 29 and 30: Statutory Reports • Business Resp
Page 39: Statutory Reports • Business Resp
Page 43 and 44: Statutory Reports • Management Di
Page 57 and 58: Statutory Reports • Corporate Gov
Page 73 and 74: Statutory Reports • Additional Sh
Page 87 and 88: Statutory Reports • Board’s Rep
Page 89 and 90: Statutory Reports • Board’s Rep
Page 91 and 92:
Statutory Reports • Board’s Rep
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Standalone Financial Statements Ann
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Consolidated Financial Statements A
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Notice Annual Report 2014 - 15 NOTI
Page 229 and 230:
E-Voting Annual Report 2014 - 15 IN
Page 231:
Dr. Reddy’s Laboratories Limited
Page 235 and 236:
The future belongs, not to those wh
show all

Good Health Can’t Wait.

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?